Literature DB >> 32938165

Skin tests in the diagnosis of adverse drug reactions.

Luca Stingeni1, Leonardo Bianchi2, Marta Tramontana1, Paolo D Pigatto3, Cataldo Patruno4, Monica Corazza5, Caterina Foti6, Gabriella Fabbrocini7, Giuseppe Micali8, Paolo Romita6, Maddalena Napolitano9, Katharina Hansel1.   

Abstract

Adverse drug reactions (ADRs) are common and influence negatively the patient's therapeutic options. They recognize multiple pathogenic mechanisms, some of immunological origin, and the clinical manifestations involve several organs and systems, including skin and/or mucous membranes in 25-30% of patients. The identification of the trigger drug remains a medical challenge, mainly in poly-medicated patients. Anamnesis and clinical approach are crucial, but allergy work-up is the essential tool to confirm or exclude the causative role of the culprit drug. Besides in-vitro tests and drug provocation test, skin tests (ST) represent the cornerstone: patch test in delayed ADR, prick test in immediate ADR, and intradermal test in both. Nevertheless, ST are in continuous evolution and characterized by technical difficulties (concentration and vehicle) that can influence their value and specificity. In this article we review the indications and the rules in performing patch test, prick test, and intradermal test with the most commonly used drugs in Italy to determine the cause of a cutaneous and/or mucous ADR, precise the involved pathogenic mechanism, and provide a valid therapeutic alternative to the patient.

Entities:  

Year:  2020        PMID: 32938165     DOI: 10.23736/S0392-0488.20.06698-5

Source DB:  PubMed          Journal:  G Ital Dermatol Venereol        ISSN: 0392-0488            Impact factor:   2.011


  6 in total

1.  Role of Patch Testing in Chronic Spontaneous Urticaria.

Authors:  Jonathan Bar; Sari Godlewicz; Arieh Ingber; Eli Sprecher; Dan Slodownik
Journal:  J Asthma Allergy       Date:  2021-08-21

2.  Skin tests in urticaria/angioedema and flushing to Pfizer-BioNTech SARS-CoV-2 vaccine: Limits of intradermal testing.

Authors:  Leonardo Bianchi; Filippo Biondi; Katharina Hansel; Nicola Murgia; Marta Tramontana; Luca Stingeni
Journal:  Allergy       Date:  2021-04-22       Impact factor: 14.710

3.  Pityriasis rosea after Moderna mRNA-1273 vaccine: A case series.

Authors:  Fabrizio Martora; Gabriella Fabbrocini; Claudio Marasca
Journal:  Dermatol Ther       Date:  2021-12-01       Impact factor: 3.858

4.  Severe adverse drug reaction in SARS-CoV-2 infection: AGEP induced by ceftriaxone and confirmed by patch test.

Authors:  Luca Stingeni; Daniela Francisci; Leonardo Bianchi; Katharina Hansel; Marta Tramontana; Francesco Di Candilo; Massimo Raffaele Mannarino; Matteo Pirro
Journal:  Contact Dermatitis       Date:  2021-04-23       Impact factor: 6.419

5.  Comment on "Caution against injudicious vaccine allergy skin test and adverse reactions after intradermal COVID-19 vaccine testing".

Authors:  Leonardo Bianchi; Katharina Hansel; Filippo Biondi; Nicola Murgia; Marta Tramontana; Luca Stingeni
Journal:  Contact Dermatitis       Date:  2021-12-01       Impact factor: 6.600

6.  Safety of SARS-CoV-2 vaccines in psoriatic patients treated with biologics: A real life experience.

Authors:  Maria Letizia Musumeci; Giuliana Caruso; Andrea Calogero Trecarichi; Giuseppe Micali
Journal:  Dermatol Ther       Date:  2021-11-15       Impact factor: 3.858

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.